Neurology Diagnostics, Inc.

The trials here

What the 9 trials at this site are about, from their registry records.

Conditions

• Alzheimer disease5 trials
• Multiple sclerosis2 trials
• Migraine1 trial

Phase

• Phase 35 trials
• Phase 23 trials
• Phase 41 trial

Status

• Completed5 trials
• Active, not recruiting4 trials

Lead sponsor

• Eli Lilly and Company5 trials
• Novartis Pharmaceuticals2 trials
• Alzheon Inc.1 trial
• Ipsen1 trial

Running trials

• Active, not recruiting

  A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in Adults

  NCT06625060· Phase 2· Ipsen· Source

• Active, not recruiting

  Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)

  NCT05156281· Phase 3· Novartis Pharmaceuticals· Source

• Active, not recruiting

  A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)

  NCT05026866· Phase 3· Eli Lilly and Company· Source

• Active, not recruiting

  A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)

  NCT04437511· Phase 3· Eli Lilly and Company· Source

Closed trials

• Completed

  Effects of LY3848575 Versus Placebo in Participants With Painful Distal Sensory Polyneuropathy

  NCT06568042· Phase 2· Eli Lilly and Company· Source

• Completed

  A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)

  NCT05463731· Phase 3· Eli Lilly and Company· Source

• Completed

  Study to Assess the Effect of Ofatumumab in Treatment Naïve, Very Early RRMS Patients Benchmarked Against Healthy Controls.

  NCT05084638· Phase 4· Novartis Pharmaceuticals· Source

• Completed

  An Efficacy and Safety Study of ALZ-801 in APOE4/4 Early AD Subjects

  NCT04770220· Phase 3· Alzheon Inc.· Source

• Completed

  A Follow-On Study of Donanemab (LY3002813) With Video Assessments in Participants With Alzheimer's Disease (TRAILBLAZER-EXT)

  NCT04640077· Phase 2· Eli Lilly and Company· Source